<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-14T07:43:04Z</responseDate>
  <request identifier="oai:figshare.com:article/34032154" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34032154</identifier>
        <datestamp>2026-09-30T12:11:30Z</datestamp>
        <setSpec>category_1</setSpec>
        <setSpec>category_4</setSpec>
        <setSpec>category_7</setSpec>
        <setSpec>category_13</setSpec>
        <setSpec>category_15</setSpec>
        <setSpec>category_19</setSpec>
        <setSpec>category_272</setSpec>
        <setSpec>category_734</setSpec>
        <setSpec>category_61</setSpec>
        <setSpec>category_62</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>portal_63</setSpec>
        <setSpec>item_type_6</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Synthetic Development and Scale-Up of the Aminoindazole
Fragment of Lenacapavir</dc:title>
          <dc:creator>Lennie Lin (10751217)</dc:creator>
          <dc:creator>Anna M. Wagner (1837234)</dc:creator>
          <dc:creator>Jason Davy (25143805)</dc:creator>
          <dc:creator>Chloe Y. Wong (25143808)</dc:creator>
          <dc:creator>Wen-Tau T. Chang (2389168)</dc:creator>
          <dc:creator>B. Michael O’Keefe (1530931)</dc:creator>
          <dc:creator>Alexander F. G. Goldberg (9630041)</dc:creator>
          <dc:creator>Huy Van Huynh (25143811)</dc:creator>
          <dc:creator>Hongwei Sun (422270)</dc:creator>
          <dc:creator>Wei Wang (17594)</dc:creator>
          <dc:creator>Scott A. Wolckenhauer (2283733)</dc:creator>
          <dc:subject>Biophysics</dc:subject>
          <dc:subject>Biochemistry</dc:subject>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Genetics</dc:subject>
          <dc:subject>Neuroscience</dc:subject>
          <dc:subject>Pharmacology</dc:subject>
          <dc:subject>Environmental Sciences not elsewhere classified</dc:subject>
          <dc:subject>Biological Sciences not elsewhere classified</dc:subject>
          <dc:subject>Developmental Biology</dc:subject>
          <dc:subject>Marine Biology</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>purpose ” large</dc:subject>
          <dc:subject>mediated nitrile formation</dc:subject>
          <dc:subject>key improvements include</dc:subject>
          <dc:subject>initial “ fit</dc:subject>
          <dc:subject>final product quality</dc:subject>
          <dc:subject>drug recently approved</dc:subject>
          <dc:subject>&gt;- sulfonic acid</dc:subject>
          <dc:subject>commercially viable process</dc:subject>
          <dc:subject>development efforts improved</dc:subject>
          <dc:subject>1 &lt;/ b</dc:subject>
          <dc:subject>yielding process</dc:subject>
          <dc:subject>process safety</dc:subject>
          <dc:subject>yeytuo ).</dc:subject>
          <dc:subject>synthetic development</dc:subject>
          <dc:subject>step route</dc:subject>
          <dc:subject>significant overhaul</dc:subject>
          <dc:subject>hydroxylamine -&lt;</dc:subject>
          <dc:subject>exposure prophylaxis</dc:subject>
          <dc:subject>describe herein</dc:subject>
          <dc:subject>alternative condition</dc:subject>
          <dc:subject>acting treatment</dc:subject>
          <dc:description>We
describe herein the development and scale-up of the aminoindazole
fragment of lenacapavir, a drug recently approved for long-acting
treatment of HIV (Sunlenca) and pre-exposure prophylaxis (as Yeztugo
and Yeytuo). This five-step route to fragment &lt;b&gt;1&lt;/b&gt; was developed
from the initial “fit-for-purpose” large-scale synthesis
to a commercially viable process. Key improvements include an alternative
condition to hydroxylamine-&lt;i&gt;O&lt;/i&gt;-sulfonic acid-mediated
nitrile formation and a significant overhaul of the key Miyaura borylation
process. The culmination of all development efforts improved the final
product quality and process safety, resulting in a more efficient
and higher-yielding process.</dc:description>
          <dc:date>2026-09-30T00:00:00Z</dc:date>
          <dc:type>Text</dc:type>
          <dc:type>Journal contribution</dc:type>
          <dc:identifier>10.1021/acs.oprd.6c00302.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/journal_contribution/Synthetic_Development_and_Scale-Up_of_the_Aminoindazole_Fragment_of_Lenacapavir/34032154</dc:relation>
          <dc:rights>CC BY-NC 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
